Neurodiagnostics Market Report 2026

Neurodiagnostics Market Overview

• Neurodiagnostics market size has reached to $9.79 billion in 2025 • Expected to grow to $13.48 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Prevalence Of Neurological Disorders Driving Growth In The Market • Market Trend: Advancements In AI-Driven Software For Enhanced Diagnostic Accuracy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurodiagnostics Market?

Neurodiagnostics refers to the medical field focused on diagnosing and monitoring disorders of the nervous system, including the brain, spinal cord, and peripheral nerves. It involves the use of advanced technologies and tests to assess neurological function, identify abnormalities, and aid in the diagnosis of conditions such as epilepsy, stroke, multiple sclerosis, neuropathies, and other neurological diseases. The main types of neurodiagnostic are diagnostic and imaging solutions and in-vitro diagnostics. Diagnostic and imaging solutions involve medical technologies and services designed to diagnose health conditions using various imaging techniques and diagnostic tools. Key technologies include neuroimaging, computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine imaging (PET, SPECT), near-infrared spectroscopic imaging (NIRS), electroencephalography (EEG), magnetoencephalography (MEG), voxel-based morphometry (VBM), and neuroinformatics. These diagnostic tools are essential in the treatment of conditions such as epilepsy, alzheimer's disease, parkinson's disease, stroke, joint health issues, and others and are utilized in hospitals, clinics, diagnostic laboratories, imaging centers, and others.

What Is The Neurodiagnostics Market Growth Forecast?

The neurodiagnostics market size is expected to see strong growth in the next few years. It will grow to $13.48 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to expansion of biomarker-based diagnostics, increasing investment in neuroimaging innovation, rising adoption of digital neuroinformatics platforms, development of portable and wearable neurodiagnostic devices, growing demand for point-of-care neurological testing. Major trends in the forecast period include increasing adoption of advanced neuroimaging modalities, growing use of in-vitro neurodiagnostic biomarkers, rising demand for early detection of neurological disorders, expansion of eeg and meg for real-time brain monitoring, increasing focus on non-invasive and minimally invasive diagnostics.

Global Neurodiagnostics Market Segmentation

1) By Type: Diagnostic And Imaging Solutions, In-Vitro Diagnostics 2) By Technology: Neuroimaging Technologies, Nuclear Medicine Imaging, Near Infrared Spectroscopic Imaging (NIRS), Magneto-Encephalography (MEG), Voxel Based Morphometry (VBM), Neuroinformatics 3) By Condition: Epilepsy, Alzheimer's Disease, Parkinson's Disease, Stroke, Other Conditions 4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Imaging Centers, Other End Uses Subsegments: 1) By Diagnostic And Imaging Solutions: MRI (Magnetic Resonance Imaging) Systems, CT (Computed Tomography) Scanners, EEG (Electroencephalogram) Systems, EMG (Electromyography) Systems, MEG (Magnetoencephalography) Systems, PET (Positron Emission Tomography) Scanners, SPECT (Single Photon Emission Computed Tomography) Scanners, Functional MRI (fMRI) Systems, Intracranial Pressure Monitors 2) By In-Vitro Diagnostics: Blood-Based Diagnostics, Cerebrospinal Fluid (Csf) Analysis, Genetic Testing And Biomarkers, Neurochemical Diagnostics, Point-Of-Care Neurodiagnostics, Diagnostic Kits For Neurodegenerative Disorders

What Is The Driver Of The Neurodiagnostics Market?

The increasing prevalence of neurological disorders is expected to drive the growth of the neurodiagnostics market going forward. Neurological disorders are conditions that impact the brain, spinal cord, or nerves, leading to various cognitive, motor, and sensory impairments. The rise in neurological disorders is largely due to aging populations, environmental factors, lifestyle changes, genetics, and better diagnostic techniques. Neurodiagnostics are essential for accurately identifying, assessing, and monitoring neurological disorders, enabling precise diagnosis, informed treatment decisions, and effective management of conditions affecting the brain, spinal cord, and nerves. For instance, in April 2023, according to the National Library of Medicine, a US-based medical library for medical research information, it was reported that, in 2023, 6.7 million Americans are affected by Alzheimer's, and this number is expected to grow to 13.8 million by 2060. Therefore, the increasing prevalence of neurological disorders is driving the growth of the neurodiagnostics industry.

Key Players In The Global Neurodiagnostics Market

Major companies operating in the neurodiagnostics market are Nihon Kohden Corporation, Cephalon LLC, Stratus Neuro LLC, Cadwell Industries Inc., Compumedics Limited, Ceribell Inc., CND Life Sciences Inc., Lifelines Neuro Inc., ANT Neuro B.V., Neurovative Diagnostics LLC, Firefly Neuroscience Inc, IntraNerve Neuroscience Inc, NeuroDiagnostics Laboratories LLC, Advanced Brain Monitoring Inc, Spes Medica S.r.l., BioSignal Group Inc, Combinostics Inc., Deymed Diagnostic LLC, NeuLine Health Inc., Ridge Diagnostics Inc., Beacon Biosignals Inc., Intch Inc.

Global Neurodiagnostics Market Trends and Insights

Major companies operating in the neurodiagnostics market are focusing on technological advancements such as an advanced software algorithm to enhance diagnostic accuracy and improve patient outcomes. An advanced software algorithm refers to a sophisticated set of instructions that processes and analyzes data using techniques such as artificial intelligence (AI) or machine learning to enhance decision-making and diagnostics. For instance, in October 2023, Ceribell Inc., a US-based medical equipment manufacturing company, launched the ClarityPro AI algorithm, marking a significant advancement in diagnosing electrographic status epilepticus (ESE). This state-of-the-art software, integrated into the Ceribell EEG system, leverages machine learning to analyze EEG waveforms and deliver real-time alerts for suspected seizures. Notably, ClarityPro is the first acute care device to receive FDA clearance for standalone diagnosis. This innovative technology is designed to improve clinical decision-making by continuously monitoring brain activity, offering actionable insights, and enabling faster and more effective treatment responses.

What Are Latest Mergers And Acquisitions In The Neurodiagnostics Market?

In October 2025, Natus Medical Incorporated, a US-based medical device company, acquired Holberg EEG for an undisclosed amount. With this acquisition, Natus aims to enhance its neurodiagnostic capabilities by integrating Holberg’s advanced artificial intelligence–driven EEG interpretation technology into its existing product portfolio to improve diagnostic accuracy and workflow efficiency. Holberg EEG is a Norway-based provider of AI-powered electroencephalogram (EEG) interpretation solutions.

Regional Outlook

North America was the largest region in the neurodiagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurodiagnostics Market?

The neurodiagnostics market includes revenues earned by entities by providing services such as electroencephalography (EEG), positron emission tomography (PET), cerebrospinal fluid (CSF) analysis, and sleep apnea diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodiagnostic market consists of sales of transcranial magnetic stimulation (TMS) devices, magnetoencephalography (MEG) systems, polysomnography (PSG) devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurodiagnostics Market Report 2026?

The neurodiagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurodiagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.